Boehringer Ingelheim

This study is testing two new drugs, BI 765049 alone and combined with ezabenlimab, in Asian adults with advanced cancers that have a specific marker called B7-H6. The main goals are to find the highest safe dose patients can tolerate and to see if the treatments cause tumors to …

This is the first study in humans to test a new drug called BI 764532 for people with advanced small cell lung cancer and similar neuroendocrine cancers that have not responded to standard treatments. The main goal is to find the highest dose and best schedule that patients can s…

This large, late-stage study is testing whether a weekly injection called survodutide can prevent serious liver complications in people who already have advanced scarring (cirrhosis) from fatty liver disease (NASH/MASH). About 1,590 adults will be randomly assigned to receive eit…

This early-stage study is testing a new drug called BI 765049 in adults with advanced colorectal, stomach, or pancreatic cancer that has spread or cannot be removed by surgery. The main goal is to find the highest dose patients can safely tolerate and determine the best way to gi…

This study is testing a new immunotherapy drug called BI 3820768 for the first time in people. It's for adults with advanced germ cell, endometrial, or ovarian cancer that has returned or stopped responding to standard treatments. The main goal is to find a safe and tolerable dos…

This large study is testing whether adding a new oral drug called vicadrostat to an existing diabetes medicine (empagliflozin) provides better protection against heart and kidney problems in adults who have type 2 diabetes, high blood pressure, and existing heart disease. About 1…

This large international study is testing whether adding a new investigational drug called BI 690517 to an existing kidney medication (empagliflozin) can better protect people with chronic kidney disease. The goal is to slow kidney function decline and reduce hospitalizations for…

This study is testing if an intravenous medicine called spesolimab can help close painful skin ulcers caused by pyoderma gangrenosum, a rare inflammatory skin condition. It will involve about 90 adults with active ulcers, comparing spesolimab against a placebo infusion over about…

This study is testing whether a new oral medicine called BI 764198 can help people with a serious kidney disease called focal segmental glomerulosclerosis (FSGS). About 286 adults and teenagers will take either the real medicine or a placebo pill daily for two years, while contin…

This large, late-stage study is testing whether adding a new drug called vicadrostat to an existing heart failure medicine (empagliflozin) is better at controlling the disease. It will involve about 4,200 adults with chronic heart failure who have reduced heart pumping function. …

This is the first study in people to test a new drug called BI 1703880 when given with an existing immunotherapy drug, ezabenlimab. The main goal is to find the safest and most effective dose of the new combination for adults with advanced solid tumors that have not responded to …

This early-stage study is testing whether adding a new experimental drug (BI 770371) to standard immunotherapy treatments helps shrink tumors in people with advanced head and neck cancer that has spread or returned. The trial will enroll 90 adults and randomly assign them to one …

This study is testing whether a daily pill called zongertinib can help people with early-stage lung cancer live longer without their cancer returning after surgery. It compares the pill to standard treatments for up to 3 years in 400 adults whose cancer has a specific HER2 gene c…

This study is testing a new medicine called BI 764524, given as an injection into the eye, to see if it can improve or control moderate-to-severe diabetic retinopathy. Over 72 weeks, researchers will compare different dosing schedules of the new drug against sham (fake) injection…

This study is testing whether a new oral medicine called nerandomilast can slow down lung scarring in people whose autoimmune disease has affected their lungs. It involves 400 adults whose lung function has not improved with standard treatments. Participants will take either the …

This study is testing if a clot-busting drug called tenecteplase can help people recover from a stroke even when given more than 4.5 hours after symptoms start. It includes adults who had a stroke or woke up with one, and brain scans show there is still tissue that might be saved…

This study is testing a new medicine, BI 3802876, for adults with advanced liver scarring (cirrhosis) caused by a type of fatty liver disease called MASH. The main goal is to see how safe the medicine is and how the body handles it. About 30 participants will be randomly assigned…

This study is testing if a medicine called empagliflozin can help protect kidney function in children and teenagers with chronic kidney disease. About 120 participants, aged 2 to 17, will be randomly assigned to take either the drug or a placebo pill for six months, followed by a…

This large, late-stage study is testing whether a daily pill called BI 1291583 can reduce the frequency of painful flare-ups in people with bronchiectasis, a chronic lung condition. About 1,755 participants aged 12 and up who experience these flare-ups will be randomly assigned t…

This study is testing a new drug called BI 764532 for adults with advanced small cell lung cancer or other neuroendocrine cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe and effective dose and to see if the drug can shrin…

This study is testing whether a new oral pill called BI 1815368 can improve vision in adults with diabetic macular edema, a swelling in the eye that can cause blindness. About 300 participants will be randomly assigned to take either the study pill or a placebo (a dummy pill) twi…

This study is testing a new oral drug called zongertinib for adults with advanced HER2-positive cancers that have spread and stopped responding to prior treatments. The main goals are to find the safest and most effective dose of zongertinib when given alone or combined with othe…

This early-stage study is testing a new drug called BI 764532, given by IV along with standard chemotherapy, for adults with an aggressive type of neuroendocrine cancer. The main goal is to find the safest and most tolerable dose of the new combination. Researchers will also chec…

This study is testing whether a new obesity medication called survodutide helps the body burn fat and use energy more efficiently than an existing drug called semaglutide. Researchers will enroll 60 adults with obesity and randomly assign them to receive either survodutide or sem…

This is a first-in-human study testing a new drug called BI 1831169 for adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the highest safe dose of the drug when given alone and when combined with an existing immunoth…

This study aims to see if two different versions of the drug survodutide work the same way in the body. It will involve 80 adults who are living with overweight or obesity. Participants will receive both drug versions in a random order to compare how much of the drug gets into th…

This study is testing whether a weekly injection called survodutide can improve liver health in adults with MASH, a serious fatty liver disease that causes scarring. About 1,800 participants will be randomly assigned to receive either the real medicine or a placebo (dummy shot) f…

This study is testing whether an experimental drug called BI 765423 can help people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. About 71 adults with IPF will receive either the drug or a placebo via monthly IV infusions for 3 months, while researche…

This study is testing whether a daily pill called zongertinib can help control advanced cancers that have specific changes in a protein called HER2. It is for adults whose cancer has continued to grow despite previous treatments. Doctors will check if the medicine shrinks tumors …

This study is for people with progressive lung scarring diseases who previously took BI 1015550 in another trial. Researchers want to see how well people tolerate this medication long-term and whether it helps preserve lung function and delay serious health events. Participants t…

This study aims to find out if starting two kidney medications, vicadrostat and empagliflozin, at the same time works better for controlling kidney disease than starting them one after the other. It will involve about 416 adults whose chronic kidney disease is at risk of getting …

This large Phase 3 trial is testing whether adding a new drug called vicadrostat to an existing heart failure medication (empagliflozin) is more effective at preventing serious heart problems. The study will enroll 6,000 adults with symptomatic heart failure but preserved heart p…

This study is testing if a new oral medicine called zongertinib works better than the current standard IV treatment for adults with advanced lung cancer that has a specific genetic change (HER2 mutation). Participants, who have not yet received treatment for their advanced cancer…

This study is testing whether a drug called nerandomilast can prevent or slow down lung scarring in people who are at high risk because they have a family history of pulmonary fibrosis and early signs of lung changes on a scan. Participants, who are 40 or older, will take either …

This study is testing if a new oral medicine, BI 1356225, can help improve impulse control in adults with opioid addiction who are already taking buprenorphine treatment. About 60 participants will be randomly assigned to take either the new medicine or a placebo pill for 8 days …

This study aims to understand how a common IPF medication, pirfenidone, affects the levels of a newer drug, BI 1015550, in the bloodstream. It involves about 20 adults with idiopathic pulmonary fibrosis (IPF) who will take both drugs according to a specific schedule. Researchers …

This study is testing whether two different ways of giving the drug survodutide—using a pre-filled syringe versus a pre-filled pen—work the same way in the body. It involves 56 healthy adults or adults with overweight or obesity. Researchers will take regular blood samples to mea…

This early-stage study aims to understand how a new weight-loss drug candidate, BI 456906, affects specific targets in the liver and pancreas compared to an approved drug, semaglutide. It will enroll 30 adults with obesity and use special medical scans to see how much of these dr…

This is an early safety study for a new drug called BI 3776528. It will test how safe the drug is and how the body processes it in healthy male volunteers. The study will give some participants the drug and others a placebo to compare the effects.

This early study aims to understand how a new drug called BI 764532 moves through the body and into tumors in adults with advanced small cell lung cancer or other neuroendocrine cancers that have stopped responding to standard treatments. Participants receive the drug and then un…

This study aims to understand how different levels of liver problems affect how the body processes a new medicine called BI 1584862. It involves adults with mild, moderate, or severe liver impairment, as well as healthy matched participants for comparison. Each participant receiv…

This is an early-stage study to check the safety and how the body processes a new drug called BI 3031185. It will involve 60 healthy male volunteers who will take the drug or a placebo for a period of time. The main goal is to see how well the drug is tolerated and to measure its…

This early-stage study aims to understand the safety and side effects of a new medicine called BI 3031185 in adults with borderline personality disorder or ADHD. About 96 participants will take either the medicine or a placebo pill during short stays at a clinic, then switch trea…

This early-stage study aims to understand how liver problems affect how much of a new drug, BI 1291583, gets into a person's bloodstream. The drug is being developed to treat bronchiectasis, a chronic lung disease. Researchers will compare blood levels in 32 adults with varying d…